Clinical Trial: Transmission-Blocking Vaccine Pvs230D1-EPA/Matrix-M in Healthy Malaria-Naive Adults Using a Plasmodium Vivax Controlled Human Malaria Infection and Transmission Model

U.S., Nov. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07930585) titled 'Transmission-Blocking Vaccine Pvs230D1-EPA/Matrix-M in Healthy Malaria-Naive Adults Using a Plasmodium Vivax Controlled Human Malaria Infection and Transmission Model' on Nov. 07.

Brief Summary: Background:

Malaria is a disease caused by parasites spread by mosquito bites. Researchers want to test a vaccine that could stop mosquitoes from picking up these parasites when they bite infected people. This could stop malaria from spreading.

Objective:

To test a study vaccine (Pvs230D1-EPA/MM) to stop malaria transmission in healthy adults.

Eligibility:

Healthy people aged 18 to 54 years. People who already received the vaccine durin...